Abstract Duchenne muscular dystrophy is the most severe childhood form of muscular dystrophy caused by mutations in the gene responsible for dystrophin production. There is no cure, and treatment is limited to glucocorticoids that prolong ambulation and drugs to treat the cardiomyopathy. Multiple treatment strategies are under investigation and have shown promise for Duchenne muscular dystrophy. Use of molecular-based therapies that replace or correct the missing or nonfunctional dystrophin protein has gained momentum. These strategies include gene replacement with adeno-associated virus, exon skipping with antisense oligonucleotides, and mutation suppression with compounds that "read through" stop codon mutations. Other strategies include cell therapy and surrogate gene products to compensate for the loss of dystrophin. All of these approaches are discussed in this review, with particular emphasis on the most recent advances made in each therapeutic discipline. The advantages of each approach and challenges in translation are outlined in detail. Individually or in combination, all of these therapeutic strategies hold great promise for treatment of this devastating childhood disease.
Introduction
Duchenne muscular dystrophy (DMD) is the most common severe childhood form of muscular dystrophy resulting from mutations in the X-linked DMD gene. The most recent data compiled from worldwide newborn screening studies indicate that birth prevalence is about 1:5,000 [1••] . Given the very large size of the DMD gene [2] spontaneous mutations lead to an unparalleled number of sporadic cases and new carriers. Thus, the disease will never be eradicated with genetic screening and this mandates the need for an effective treatment. The disease is detected early in life owing to early disease manifestations. Serum creatine kinase levels are elevated at birth, and motor and even speech milestones are often delayed. Reduced motor skills between age 3-5 years typically provoke diagnostic evaluation. Quality of life for DMD boys is affected early in life, with inability to keep up with peers and loss of ambulation by 12 years of age [3] . Improved practices in protection of the respiratory system often unmask declines in cardiac function, dictating a need for treatment of the dilated cardiomyopathy. DMD is relentlessly progressive, and the medical need for treatment is undeniable. This review will summarize the growing body of strategies that are under investigation for treatment of DMD, with particular emphasis on the most recent observations.
Gene Replacement
Multiple treatment strategies are under development for both the primary gene defect and secondary complications of DMD; however, replacing the defective gene using adeno-associated virus (AAV) remains a promising approach for meaningful and long-term correction. AAV is nonpathogenic, remains stable in nonreplicating cells (i.e., muscle), and multiple serotypes, including AAV1, AAV6, AAV8, and AAV9, exhibit tropism for muscle. One caveat for AAV delivery as a treatment for DMD is the large size of the dystrophin gene, which exceeds the packaging capacity of AAV (less than 5 kb). Fortunately, there has been intense effort to develop an AAV-based therapeutic which bypasses the packaging constraint. The first strategy was the development of minidystrophins and microdystrophins. The modular structure of dystrophin allows some functional flexibility; deletions of nonessential coding regions, namely, spectrin repeats and the C-terminus, allow dystrophin to retain significant function if the reading frame is intact (Fig. 1a) . This phenomenon was initially based on a clinical observation in a Becker muscular dystrophy patient with a large in-frame deletion of exons 17-48 removing a significant portion of the rod domain [4] . The patient remained ambulatory until age 61 years despite the absence of 46 % of the dystrophin gene. This sparked investigations by numerous groups to establish the optimal dystrophin domains fulfilling two conditions: fitting the size limitations of AAV and demonstrating therapeutic efficacy [5, 6] . On the basis of these principles, minidystrophins were tested and showed reversal of the dystrophic phenotype and functional improvement in the mdx mouse model for DMD [7, 8] . These proof-of-principle studies provided the impetus for the first clinical trial with minidystrophin [9••] . This initial clinical trial for DMD defined potential obstacles regarding immune response to consider for future attempts to restore dystrophin using gene replacement. An important finding was the presentation of novel foreign epitopes resulting from delivery of a minidystrophin complementary DNA that expressed exogenous dystrophin in the region of the endogenous deletion. This experience has heightened awareness that not all mutations are necessarily amenable to gene replacement and that patients must be carefully chosen as part of prescreening for future gene therapy trials.
Additional strategies to deliver larger minidystrophin genes that exceed the packaging capacity of AAV are under investigation to establish proof of principle for translation to the clinic. This approach uses dual vectors delivered simultaneously, allowing reconstitution of a larger functional dystrophin gene in vivo (Fig. 1) . In one study, Odom et al. [10•] expressed a highly functional 6.2-kb minidystrophin gene containing the C-terminal signaling domain using this AAVmediated homologous recombination strategy (Fig. 1) . The two transgene cassettes used in this experimental paradigm shared an overlap of 372 bp, allowing the full-length minigene to be generated in vivo following homologous recombination. Functional studies demonstrated that the recombined minigene exhibiting expression in 41.7 % of muscle fibers led to a greater improvement in peak force and protection from eccentric-contraction-induced injury than a smaller microdystrophin gene fitting within AAV packaging limits and exhibiting expression in 72.6 % of muscle fibers. These results emphasize the significance of including dystrophin functional domains such as the C-terminus to meaningfully improve muscle function. A second dual vector approach employs the use of synthetic intron splicing signals, which leads to reconstitution of the gene following delivery to muscle (Fig. 1) . Using this trans-splicing strategy, the Duan laboratory developed a series of minidystrophin dual vectors and packaged them using AAV6 [11] . The minidystrophin vectors included the neuronal nitric oxide synthase (nNOS) binding site encoded by spectrin repeats 16 and 17. When activated by calcium, nNOS generates nitric oxide (NO), a critical regulator of muscle force [12] . Mislocalization of the musclespecific nNOS (nNOSμ) in DMD is thought to contribute to muscle weakening. Following intramuscular injection in mdx mice, the minidystrophin reconstituted through trans-splicing and restored a minidystrophin that included nNOSμ expression and its concomitant activity. Additional studies will be necessary to validate the functional significance of restoring nNOS activity in DMD muscle. Homologous recombination b A trans-splicing approach is a dual vector strategy in which the transgene cassette is divided in two, whereby a splice donor (SD) site is added to the 5' vector and a splice acceptor (SA) site is added to the 3' vector. Upon codelivery to muscle, the vectors concatamerize and undergo splicing to generate a fulllength transcript. c A second dual vector strategy employs an overlap sequence that is shared by both vectors (asterisk). Following delivery to muscle, homologous recombination between the two vectors occurs to generate full-length transcript. YFMG your favorite muscle gene strategies have also been applied to gene delivery in limb girdle muscular dystrophy type 2B [13, 14] in preclinical studies. In addition, our group has demonstrated unexpected plasticity of the AAV5 serotype [15] . Without attempting to provide overlapped regions for homologous recombination, AAV5 spontaneously partially packaged two halves of a dysferlin transgene, yielding virions with a region of homology that resulted in dual vectors expressing a full-length transgene. The future of gene replacement for treatment of muscular dystrophies resulting from mutations in large genes such as dystrophin and dysferlin will most likely incorporate the use of modified AAV strategies to maximize functional efficacy.
Exon Skipping
Exon skipping is a molecular treatment approach with considerable promise for a large portion of the DMD population, potentially applicable to 60-80 % of DMD gene mutations, which cause frame-shifting. It is targeted at the pre-messenger RNA level, allowing one or more exons to be omitted to restore the dystrophin reading frame. This is accomplished with antisense oligonucleotides (AONs) that are synthesized to hybridize in a complementary fashion to pre-messenger RNA, resulting in splicing modification. Preclinical efficacy has been demonstrated in the mdx mouse, dystrophin/utrophin knockout mouse, and CXMD dog [16] [17] [18] . Two phase I intramuscular safety trials were conducted in DMD patients targeting exon 51 using AONs with two different chemical backbones, 2-O-methyl-RNA with a phosphorothioate backbone (2¢O-MePS; PRO051, Prosensa) and a phosphorodiamidate morpholino oligomer (PMO; eteplirsen, Sarepta Therapeutics) [19, 20] . Safety was demonstrated in both studies limited to intramuscular injections of the AON in single muscle groups. Phase I/II extension studies were performed with both AONs to assess efficacy and tolerability following systemic delivery. In the PRO051 trial, dose-related efficacy was achieved with evidence of new dystrophin expression in approximately 60-100 % of muscle fibers in ten of 12 patients and modest improvement in the 6-min walk test [21] . In the UK, a phase II open-label study with eteplirsen-treated patients confirmed the results of exon skipping, with as many as 55 % of muscle fibers expressing dystrophin after treatment [22] .
A US phase IIb randomized, double-blind, placebocontrolled trial to assess multiple dose efficacy of eteplirsen has just been completed at Nationwide Children's Hospital (Columbus, OH, USA). After 6 months, dystrophin was expressed in 23±6 % of muscle fibers and the distance walked in the 6-min walk test showed a change from the baseline of 28 m compared with placebo. An open-label trial was extended for 1 year, and compared with the baseline, 47 % of muscle fibers expressed dystrophin, and the distance on the 6-min walk test improved by 89 m (p≤0.016) compared with placebo [23••] . Two boys in the trial improved their walking distance by 65 and 63 m compared with the baseline (J.R.
Mendell, unpublished results).
Both 2′O-MePS-and PMO-based AONs have limited transduction efficiency in the heart as demonstrated in preclinical studies in mdx mice. Although safety and efficacy in skeletal muscle is currently being evaluated in clinical trials, development of peptide-conjugated AONs is under way to transduce both heart and skeletal muscle more efficiently. These include PMOs conjugated to arginine-rich cellpenetrating peptides [24] or other PMOs fused with a muscle-specific peptide [25] . Studies in mdx mice using either mode of enhancement targeting exon 23 showed nearly 100 % transduction efficiency in skeletal muscle and up to 40 % in cardiac muscle [24, 25] . Cardiac expression of PMO-induced dystrophin expression is of considerable importance considering that unconjugated PMOs incapable of myocardial dystrophin restoration worsened myocardial disease in long-term in mdx mouse studies [26] . This implies that rescuing skeletal muscle activity through dystrophin expression in the absence of cardiac expression may have negative consequences for cardiomyocytes, perhaps related to stress of increasing activity. Formulating AONs to improve cardiac transduction will be necessary to achieve satisfactory results with exon skipping alone, or will require alternative cardiotherapy using any one of multiple approaches [27] [28] [29] [30] [31] .
Mutation Suppression
Stop codon mutations in the DMD gene constitute approximately 15 % of all DMD cases [32] . The goal of mutation suppression is to read through a premature stop codon (also called nonsense mutations) to generate full-length dystrophin protein. Two pharmacologic tactics have shown preclinical efficacy and have also been tested clinically. A proof-of-principle study in mdx mice demonstrated in vivo mutation suppression with functional benefit using the aminoglycoside antibiotic gentamicin [33] . In a subsequent clinical trial, in DMD patients (n=16) with stop codons treated weekly or twice weekly for 6 months (7.5 mg/kg intravenously), there was a modest increase in the number of muscle fibers expressing dystrophin, reaching 13 and 15 % of normal. Functional correlates included stabilization of muscle strength and a modest increase in forced vital capacity. Although this study demonstrated proof of principle demonstrating gentamicin-induced dystrophin expression in a clinical setting, it is clear that higher doses would be necessary to improve functional outcomes for patients. Given the potential renal toxicity of aminoglycoside antibiotics and the need for regular intravenous infusions, attention shifted to safer pharmacologic products producing mutation suppression, especially those that could be administered orally.
A second drug, ataluren, formerly referred to as PTC124 (PTC Therapeutics), demonstrated promise as an orally administered pharmacologic read-through agent for stop codon mutations [34] . Preclinical studies in the mdx mouse demonstrated dystrophin expression in skeletal, cardiac, and diaphragm muscle with protection against eccentriccontraction-induced injury. A phase I study in healthy volunteers established safety and tolerability at doses exceeding those required for preclinical efficacy [35] . Dystrophin expression also increased after treatment in a phase IIa proofof-concept 28-day study in DMD/Becker muscular dystrophy patients. Subsequently, a randomized, double-blind, placebo-controlled phase IIb trial was conducted evaluating safety and efficacy over a 48-week treatment period. In a press release, PTC Therapeutics concluded that preliminary results indicated a convincing safety profile, but the primary end point of the 6-min walk test did not reach statistical significance [36] .
Recently, two new read-through compounds called RTC13 and RTC14were identified in a high-throughput screen. A preclinical study in mdx mice demonstrated modest results with RTC14; however, RTC13 demonstrated higher levels of read-through accompanied by improved muscle function and increased dystrophin expression in skeletal muscle, diaphragm, and heart following systemic delivery. The study compared RTC13 with gentamicin and ataluren and showed it outperformed both compounds [37] . Further testing will be necessary to establish the safety and tolerability of RTC13, but this preclinical study offers hope for the treatment of DMD patients as well as other dystrophies caused by nonsense mutations.
Dystrophin Surrogates
There are a growing number of therapeutic strategies based on the concept of upregulating or overexpressing alternative genes to compensate for the loss of dystrophin [9] . In the face of potential immunity to exogenously expressed dystrophin in DMD patients, these approaches are particularly attractive. Utrophin, a developmental paralog of dystrophin, by upregulation or replacement of dystrophin was the first surrogate to show promise as a treatment for DMD. Utrophin shares 80 % sequence homology with dystrophin and has been shown to partially restore function in the absence of dystrophin in transgenic mice [38] or preclinical gene replacement studies [39] . Utrophin is expressed at the sarcolemma during development but is limited to the neuromuscular and myotendinous junctions in adult normal muscle. However, in both dystrophic mice and DMD patients it is overexpressed in the sarcolemma of all muscle fibers, partially compensating for the lost mechanical function of dystrophin in the membrane. Alternative strategies to further exploit this phenomenon have emerged to upregulate utrophin at the sarcolemma, including several small molecules which demonstrate transcriptional upregulation through the utrophin-A promoter [40] [41] [42] . In addition to utrophin, a number of studies have shown improvement in mdx mice with other genes, including recombinant human biglyan, a 7 integrin, synaptic cytotoxic T-cell GalNAc transferase (Galgt2), sarco/endoplasmic reticulum Ca 2+ -ATPase, heat shock protein72, and L-arginine [43] [44] [45] [46] [47] [48] . The overexpression of many of these genes results in the upregulation of dystrophin-associated proteins and also in the amount of utrophin. Although improvement has been demonstrated in the mdx mouse, results have been restricted to preservation rather than marked functional improvement. As a class of drugs, dystrophin surrogates may have the greatest potential in combination with dystrophin correction or replacement strategies.
Cell Therapy
Recurrent episodes of muscle fiber breakdown and regeneration characteristic of DMD result in impaired satellite cell differentiation, loss of muscle fibers, and replacement by fat and connective tissue. As a result, strategies to deliver normal or genetically corrected muscle cells or pluripotent stem cells have long been under investigation. Although myoblast transfer initially showed promise in the mdx mouse [49] , subsequent clinical trials were disappointing owing to immune rejection, failure to disperse from the site of injection, or poor cell fusion and survival [50, 51] . Various stem-cell-myogenic precursor populations address some of these difficulties by offering the capacity to proliferate and the ability to migrate via the vasculature. These populations include satellite cells, muscle-derived stem cells, side population cells, bone-marrow-derived stem cells, and mesangioblasts [52] [53] [54] [55] [56] . Of these approaches, mesangioblasts demonstrated particular promise as multipotent progenitors: an exhibited potential for improving muscular dystrophy, ease of isolation from blood vessels, and their capacity for arterial transmigration [57] . The experimental paradigm is to use the mesangioblasts as delivery vehicles for the DMD gene. A series of studies in mdx mice and the golden retriever muscular dystrophy (GRMD) dog showed that mesangioblasts transduced with a lentiviral vector expressing microdystrophin resulted in expression of dystrophin-positive fibers. Notably, the studies in GRMD dogs revealed improvements in muscle function and mobility together with increased levels of dystrophin [58] . There remains some concern regarding the disconnect between limited dystrophin replacement and the high degree of functional correction observed. In addition, the potential contribution of immunosuppressive drugs used in combination with these preclinical studies to the degree functional improvement in the treated GRMD dogs has not been fully addressed [59] .
Impediments to translating cell therapies to patients with muscular dystrophy have been revealed over the past several years. The challenges parallel those for gene therapy strategies, including preference for autologous transplantation to avoid immune responses and identifying a viral vector to accommodate the large dystrophin gene [60] . The mesangioblast approach appeared to have addressed the issue of arterial dispersal; however, it was found that muscular dystrophy patients had reduced numbers of mesangioblasts, which would be insufficient for autologous cell therapy [61] . To circumvent this issue, investigators found that they could reprogram fibroblasts and myoblasts from muscular dystrophy patients and generate induced pluripotent stem cells from which mesangioblasts could be derived [61] . Such mesangioblasts have been used to genetically correct the dystrophic phenotype in a-sarcoglycan (α-SG) deficient mice using the human α-SG gene. These studies are not entirely relevant to DMD given the small size of the α-SG gene versus the inability to deliver the full-length dystrophin complementary DNA by viral vectors. Future studies may incorporate a dual vector strategy as discussed earlier to address this issue. In the meantime, Darabi et al. [62] have demonstrated proof of principle for transplantation of myogenic precursor cells derived by conditionally expressing Pax7 in human embryonic stem cells/induced pluripotent stem cells in mdx mice. Dystrophin expression derived from the human induced pluripotent stem cells was modest but led to functional improvement in the mdx mouse. Additional studies will be necessary to determine the potential for translation for patients.
Conclusion
The challenge to find a treatment for DMD continues, although current therapeutic approaches under investigation do show promise. Corticosteroids represent the standard of care for treatment of this disease. This class of drugs can make a difference by prolonging ambulation and delaying or preventing the onset of scoliosis. Gene replacement strategies offer the potential for long-term correction. Improved gene therapy vectors that encompass critical dystrophin domains together with advances in understanding ways to circumvent immune responses provide a platform for meaningful translation to patients. In addition, the clinical benefit seen with the exon-skipping drug represents a major advance for DMD treatment. Lastly, significant progress has been made for cell-therapy-based treatments and upregulation of genes that act as dystrophin surrogates. Increased expression of these alternative genes may be achieved with small molecules; therefore, it is foreseeable that therapeutic approaches will include both dystrophin restoration and compensatory molecules.
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